News & Views
Agreement Expands Global Availability of Primary Cells
Feb 11 2019
A private label partnership for the manufacture and global commercialisation of an extensive range of hematopoietic primary cells has been agreed by Lonza and US company AllCells.
The addition of the entire AllCells research portfolio of products, which has expanded Lonza’s branded cell lines is available to scientists on a global scale to further their research across an array of applications, including drug discovery, toxicity testing, cell therapy and personalized medicine.
Hematopoietic primary cells play a vital role in advancing in vitro research as they closely reflect in vivo morphology, metabolism and growth characteristics. However, obtaining those cells requires researchers to find a variety of donors and perform a series of tedious cell isolations.
“With this partnership, we aim to enable straightforward access to a wealth of viable, ready-to-use hematopoietic cells, such as mobilised peripheral blood progenitor cells,” said Mary Riley, Director of Discovery Solutions at Lonza. “All researchers will need to do is thaw and culture, while also being able to take advantage of Lonza’s strong after-sales technical support.”
Don Klabunde, CEO at AllCells, added: “By leveraging our customisation expertise, speed and flexibility to manufacture hematopoietic cells of superior viability and quality and with Lonza's extensive reach, we will improve the availability of highly purified cells from different tissue sources to enhance a variety of research needs.”
Digital Edition
LMUK 49.7 Nov 2024
November 2024
News - Research & Events News - News & Views Articles - They’re burning the labs... Spotlight Features - Incubators, Freezers & Cooling Equipment - Pumps, Valves & Liquid Hand...
View all digital editions
Events
Nov 18 2024 Shanghai, China
Nov 20 2024 Karachi, Pakistan
Nov 27 2024 Istanbul, Turkey
Jan 22 2025 Tokyo, Japan
Jan 22 2025 Birmingham, UK